Immune-activation model in Alzheimer disease

Molecular and Chemical Neuropathology

Volumn 28, Issue 1-3, 1996, Pages 105-111

  Singh, Vijendra K ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE   (United States)

Author keywords

Alzheimer disease; CNS immunity; immunoregulation; neuroimmunology; T lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN S 100; T LYMPHOCYTE RECEPTOR;

ALZHEIMER DISEASE; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL;

EID: 0029791227     PISSN: 10447393     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02815211     Document Type: Conference Paper

References (26)

1. Allore R., O'Hanlon D., Price R., Neilson K., Willard H. F., Cox D. R., Marks A., and Dünn R. J. (1988) Gene encoding the β subunit of S100 protein is on chromosome 21: implications for Down Syndrome. Science 239, 1311-1313.
2. Arispe N., Rojas E., and Pollard H. B. (1993) Alzheimer's disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. USA 90, 567-571.
3. Cserr H. F. and Knopf P. M. (1992) Cervical lymphatics, the blood brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13, 507-512.
4. Eikelenboom P., Hack C. E., Rozemuller J. M., and Stam F. C. (1989) Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. 56, 259-262.
5. Ferrari C., Sansoni P., Rowden G., Manara C., Torresani C., and DePanfilis G. (1988) One half of the CD11b+ human peripheral blood T lymphocytes expresses the S-100 protein. Clin. Exp. Immunol. 72, 357-361.
6. Gaskin F. and Fu S. M. (1992) Antineurofibrillary tangle, antineuronal and anti-beta-amyloid-protein in Alzheimer's disease and related disorders. Res. Immunol. 143, 668-670.
7. Griffin W. S. T., Stanley L. C., Ling C., White L., McLeod V., Perrot L. J., White C. L. III, and Araoz C. (1989) Brain interleukin-1 and S100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86, 7611-7615.
8. Huges R. (1994) Immunotherapy for multiple sclerosis. J. Neurol. Neurosug. Psychiat. 57, 3-6.
9. Itagaki S., McGeer P. L., and Akiyama H. (1988) Presence of T-cytotoxic suppressor and leucocyte common-antigen-positive cells in Alzheimer's disease brain tissue. Neurosci. Lett. 91, 259-264.
10. Jander S., Heidenreich F., and Stoll G. (1993) Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 43, 1809-1813.
11. Marshak D. R. (1990) SlOOb as a neurotrophic factor. Prog. Brain Res. 86, 169-181.
12. McGeer P. L. and Rogers J. (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42, 447-449.
13. McRae A., Dahlstrom A., Polinsky R., and Ling E. A. (1993) Cerebrospinal fluid microglial antibodies: potential diagnostic marker for immune mechanisms in Alzheimer's disease. Behav. Brain Res. 57, 225-234.
14. McRae-Degeurce A., Booj S., Haglid K., Rosengren L., Karlsson J. E., Karlsson I., Wallin A., Svennerholm L., Gottfries C. G., and Dahlstrom A. (1987) Antibodies in the cerebrospinal fluid of some Alzheimer's disease patients recognize cholinergic neurons in the rat central nervous system. Proc. Natl. Acad. Sci. USA 84, 9214-9218.
15. Miller A. E., Neighbour A., Katzman R., Aranson M., and Lipkowitz R. (1981) Immunological studies in senile dementia of the Alzheimer's type: evidence for enhanced suppressor cell activity. Ann. Neurol. 10, 506-510.
16. Muller-Hill B. and Beyreuther K. (1989) Molecular biology of Alzheimer's disease. Annu. Rev. Biochem. 38, 287-307.
17. Rogers J., Cooper N. R., Webster S., Shultz J., McGeer P. L., Styren S. D., Civin W. H., Brachora L., Bradt B., and Lieberburg I. (1992) Complement activation by β amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 89, 10,016-10,020.
18. Singh V. K. (1990) Neuroimmune axis as a basis of therapy in Alzheimer's disease. Prog. Drug Res. 34, 383-393.
19. Singh V. K. (1994) Studies of neuroimmune markers in Alzheimer's disease. Mol. Neurobiol. 9, 73-81.
20. Singh V. K. (1996) Neuroautoimmunity: pathogenic implications for Alzheimer's disease. Gerontology (in press).
21. Singh V. K. and Fudenberg H. H. (1986) Detection of brain autoantibodies in the serum of patients with Alzheimer's disease but not Down's syndrome. Immunol. Lett. 12, 277-280.
22. Singh V. K., Fudenberg H. H., and Brown F. R., Jr. (1987) Immunologic dysfunction: simultaneous study of Alzheimer's disease and older Down's patients. Mech. Aging Devel. 37, 257-264.
23. Singh V. K., Yang Y. Y., and Singh E. A. (1992) Immunoblot detection of antibodies to myelin basic protein in Alzheimer's disease patients. Neurosci. Lett. 147, 25-28.
24. Singh V. K., Cheng J. F., and Leu S. C. (1994) Effect of substance P and protein kinase inhibitors on β-amyloid peptide-induced proliferation of cultured brain cells. Brain Res. 660, 353-356.
25. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., and Roses A. D. (1993) Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
26. Tomkinson B. E., Brown M. C., Ip S. H., Carrabis S., and Sullivan J. L. (1989) Soluble CDS during T-cell activation. J. Immunol. 142, 2230-2236.